AIM Immunotech Inc. revenue
AIM Immunotech Inc.'s revenue was $88,000 in fiscal 2025, down 48.2% on the year before. Since fiscal 2009 ($111,000) it has grown at a compound -1.4% a year. Over the last twelve months it was $95,000.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 111 | 135 | 161 | 213 | 150 | 197 | 133 | 92 | 437 | 367 | 140 | 163 | 135 | 141 | 202 | 170 | 88 | 95 |
| Growth on the year before | — | +21.6% | +19.3% | +32.3% | −29.6% | +31.3% | −32.5% | −30.8% | +375.0% | −16.0% | −61.9% | +16.4% | −17.2% | +4.4% | +43.3% | −15.8% | −48.2% | — |
| Gross profit | −473 | −1,206 | −882 | −1,776 | −1,084 | −1,054 | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| AIM Immunotech Inc. | $95,000 | -21.5% | -17.3% |
| Ibio, Inc. | $100,000 | -75.0% | -62.4% |
| Lisata Therapeutics, Inc. | $100,000 | -90.7% | — |
| Celldex Therapeutics, Inc. | $158,000 | -97.3% | -63.5% |
| Clene Inc. | $197,000 | -31.1% | -36.9% |
| Cervomed Inc. | $331,295 | -95.7% | -52.7% |
Compare with peers
- Ibio, Inc. revenue
- Lisata Therapeutics, Inc. revenue
- Celldex Therapeutics, Inc. revenue
- Clene Inc. revenue
- Cervomed Inc. revenue
Head to head: AIM vs IBIOAIM vs LSTAAIM vs CLDX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies